Recent Posts
- Drinks Industry Supplanting Government Role In Alcohol Policies In Sub-Saharan Africa
- Opinions: Future Of PEPFAR; Family Planning
- Further Progress Toward AIDS Vaccine
- Induction Of Antibodies That Block HIV Prevented By Biological Catch-22
- Research On Leishmaniasis In Ethiopia Benefits From $5 Million Grant To Hebrew U.
Random Posts
- National Survey Looks At HIV/AIDS In South Africa
- Kentucky Health Officials Join National HIV Testing Effort
- Proteomics Technology To Focus On Neurological Complications Of HIV
- California's AIDS Funding Cuts Would Be 'Catastrophic,' Says AHF
- Editorial, Opinion Piece Discuss Issues Related To Routine HIV Testing
- Columnist Discusses Recent Findings On Teenage Condom Use, HIV Prevention
- Wisconsin Issues HIV/AIDS Nonprofit Directives For Corrective Action; Clients Protest Service Inadequacies
- Montgomery County, Ala., Has Highest HIV/AIDS Rate In State
- Federal Officials To Study New Strategy To Boost HIV Testing, Treatment
- Lesotho Government, UNICEF, European Union Launch Pilot Program To Provide Financial Support To AIDS Orphans
Prescription AIDS Drugs
Contact Us
Yale Physicians Receive $4.1 Million Grant To Study New Treatment For Alcohol-Dependent HIV-Positive Inmates Transitioning Back Into Society
November 05th, 2009
Two Yale School of Medicine physicians have been awarded a $4.1 million research grant from the National Institutes of Health (NIH) to study a new pharmacological treatment for newly released HIV-positive inmates with alcohol dependence who are transitioning back into the community.
The U.S. prison population is disproportionately impacted by HIV and by alcohol and drug abuse. A majority of HIV-positive inmates also have substance abuse disorders. Though many are treated successfully for both HIV and substance abuse while incarcerated, they face enormous challenges when released.
“Released HIV-positive inmates who relapse to alcohol and drug use are less likely to adhere to HIV treatment, including antiretroviral drugs, and more likely to engage in high-risk behavior,” according to Frederick L. Altice, M.D., professor at Yale School of Medicine, director of clinical and community research at the Yale AIDS Program and one of the two principal investigators.
The prestigious NIH grant is the first of its stature for Sandra Springer, M.D., assistant professor of medicine and co-principal investigator - a junior investigator whose career has already benefited from a career development award from the NIH. In the clinical trial led by Springer and Altice, 125 HIV-positive prisoners with alcohol dependence who are transitioning back into society will receive subcutaneous (depot) injections of naltrexone. Though the medication has been previously shown to benefit those with alcohol dependence, HIV-infected individuals were never previously included in clinical trials.
All subjects in the trial, whether getting naltrexone or the placebo, will receive comprehensive case-management services and 24 weeks of counseling. “This is the first time that depot naltrexone will be formally tested in HIV-infected patients,” says Springer. She adds, “We hope to learn whether a medication known to benefit those with alcohol problems will also help assist with HIV treatment and prevent a relapse to high-risk behaviors. Our study could confirm that treating one disease, alcohol dependence, can actually fight two life-threatening conditions.”
Source
Yale University
View drug information on Naltrexone Hydrochloride Tablets.